VONCENTO (human coagulation factor VIII + von Willebrand factor)
TRANSPARENCY COMMITTEE OPINION
Opinions on drugs - Posted on Oct 12 2016
Reason for request
Extension of Inclusion
- VONCENTO has Marketing Authorisation in prophylaxis of bleeding episodes regardless of the patient's age, in the treatment of bleeding episodes or in prophylaxis and treatment of surgical bleeding in patients aged < 12 years with von Willebrand disease.
- Clinical data on its efficacy and safety represent a low level of evidence.
Clinical Added Value
|no clinical added value||
Évaluation des médicaments